COMBINED THERAPY USING INHIBITORS OF TYROSINE KINASE RECEPTORS AND INHIBITORS OF ANGIOGENESIS

摘要

FIELD: medicine, oncology, chemical-pharmaceutical industry.;SUBSTANCE: invention relates to a pharmaceutical composition designated for treatment of tumors and tumor metastasis. The composition comprises: (i) at least one antibody or its functionally intact derivative comprising a binding site that binds with the epitope ErbB1(Herl1) of receptor and (ii) at least one agent inhibiting angiogenesis being optionally in common with a pharmaceutically acceptable carrier, diluting agent or excipient used in the combined therapy in treatment of tumors and tumor metastasis. Using the proposed composition can result to the possible synergetic enhancing inhibitory effect of each specific therapeutic agent with respect to inhibition of tumor cells proliferation and providing the enhanced effective treatment as compared with individual agents using separately.;EFFECT: enhanced effectiveness of therapy.;25 cl, 1 ex